Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > National Bank On Th

<< Previous

Bullboard Posts

Next >>

Comment by SPCEO1on Jan 05, 2023 4:29pm

104 Views

Post# 35205566

RE:RE:RE:RE:RE:RE:RE:National Bank On Th

That was from way back - it came up during the FDA Advocacy hearing for Egrifta. I don't think it has been a concern ever since and I have never seen any data that suggests it is a problem.

palinc2000 wrote:
Increased risks of cancer??
As you know I am not a scientist ....Where did you see that?

PWIB123 wrote: If I remember correctly, some of the ideas expressed on why THTX would still have a viable marketplace for NASH are as follows:

1. Tesamorelin sold as EGRIFTA is already a commercialized HIV drug and could be dual labeled. Seems to reason HIV patients would change their drug regiment to include EGRIFTA to also combat NASH instead of adding another drug to their regiment.

2. Not everyone enjoys taking pills and would choose a different option if the circumstances made sense.

3. Combination therapies can enhance drug regiments and Tesamorelin may be better for the patient based on the other drugs they're already taking. This would be especially true if EGRIFTA turns out to have all the additional benefits that are also being studied.

4. Pretty sure there was data around adherance to the patients plan.

Ironically, one ofthe side effects of EGRIFTA is an increased risk of a new cancer or reactivation of a past cancer coming back.

Trogarzon wrote: Onthe Nash renewd interest I agree but Madrigal (MDGL) met both endpoints in P3 with flying colors.. like 60%+ improvement vs like 38% for THTX on top of Fibrosis improvements. Even if TH has a path forward why would they approve it when the bar has been set so hight by Madrigal.